Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Dana-Farber Cancer Institute
This is an open label, single treatment arm clinical pilot study. The study is targeted to enroll twelve evaluable patients
OBJECTIVES:
Primary
* Determine the feasibility of providing extraoral LLLT for prevention of OM in pediatric patients undergoing HCT
Secondary
* Determine the feasibility of collecting data using the WHO Oral Toxicity Scale and ChIMES in pediatric patients undergoing myeloablative HCT who are treated with extraoral LLLT for prevention of OM
* Evaluate the safety and tolerability of extraoral LLLT for prevention of OM in pediatric patients undergoing myeloablative HCT
Age
4–25
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Scheduled to undergo myeloablative conditioning followed by autologous or allogeneic hematopoietic cell transplantation at Boston Children's Hospital.
4 years of age to 25 years of age.
WHO Oral Toxicity score of 0 at baseline evaluation (first day of conditioning).
Ability to understand and the willingness to sign a written informed consent document (for patients under the age of 18 this applies to parent/guardian)
Ability to understand and/or the willingness of their parent or legally authorized representative to sign a written informed consent document.
You may not be if
Treatment with oral LLLT within 4 weeks of HCT.
Participants may not be receiving any other agents intended for the prevention/management of mucositis (including palifermin and ice chips/cryotherapy).
WHO ≥1 at baseline evaluation.
Clareo Health | Feasibility Study of Low Level Light Therapy for Prevention of Oropharyngeal Mucositis in Pediatric Transplants Patients
